APA (7th ed.) Citation

LM, W., QH, Y., L, Z., SY, L., PP, Z., X, Z., . . . TF, L. (2022). Comment on: Intravenous immunoglobulin for interstitial lung diseases of antimelanoma differentiation-associated gene 5-positive dermatomyositis: Reply. Rheumatology (Oxford, England), 61(9), e284. https://doi.org/10.1093/rheumatology/keac122

Chicago Style (17th ed.) Citation

LM, Wang, Yang QH, Zhang L, Liu SY, Zhang PP, Zhang X, Liu XJ, Han LS, and Li TF. "Comment on: Intravenous Immunoglobulin for Interstitial Lung Diseases of Antimelanoma Differentiation-associated Gene 5-positive Dermatomyositis: Reply." Rheumatology (Oxford, England) 61, no. 9 (2022): e284. https://doi.org/10.1093/rheumatology/keac122.

MLA (9th ed.) Citation

LM, Wang, et al. "Comment on: Intravenous Immunoglobulin for Interstitial Lung Diseases of Antimelanoma Differentiation-associated Gene 5-positive Dermatomyositis: Reply." Rheumatology (Oxford, England), vol. 61, no. 9, 2022, p. e284, https://doi.org/10.1093/rheumatology/keac122.